United Therapeutics (UTHR) Tax Provisions (2009 - 2026)

United Therapeutics (UTHR) has 18 years of Tax Provisions data on file, last reported at $43.4 million in Q1 2026.

• For the quarter ending Q1 2026, Tax Provisions fell 57.16% year-over-year to $43.4 million; the trailing twelve-month figure through Mar 2026 stood at $321.3 million (down 9.03% YoY), and the FY2025 full-year result was $379.2 million, up 10.26% from the prior year.
• Tax Provisions fell to $43.4 million in Q1 2026, from $79.7 million in the prior quarter.
• In the past five years, Tax Provisions ranged from a high of $101.3 million in Q1 2025 to a low of $34.6 million in Q2 2022.
• A 5-year average of $75.3 million and a median of $78.3 million in 2023 frame the typical range for Tax Provisions.
• Across the five-year window, Tax Provisions surged 1538.1% in 2022 and plunged 57.16% in 2026, its largest moves.
• Tracing UTHR's Tax Provisions over 5 years: stood at $46.7 million in 2022, then soared by 67.67% to $78.3 million in 2023, then advanced by 21.58% to $95.2 million in 2024, then retreated by 16.28% to $79.7 million in 2025, then plunged by 45.55% to $43.4 million in 2026.
• Business Quant data shows UTHR's Tax Provisions at $43.4 million in Q1 2026, $79.7 million in Q4 2025, and $99.3 million in Q3 2025.